[NMusers] AstraZeneca -> Clinical Pharmacometrican opportunities

From: Hamrén, Bengt <Bengt.Hamren_at_astrazeneca.com>
Date: Wed, 6 May 2015 10:53:12 +0000

Clinical Pharmacometricians

Quantitative Clinical Pharmacology, Early Clinical Development

Who we are

AstraZeneca is a global, innovation-driven biopharmaceutical business that =
pushes the boundaries of science to deliver life-changing medicines to pati=
ents. We focus on predictive science to move the frontier of quantitative d=
rug development where modeling and simulation (M&S) is proactively utilized=
 and provide quantitative support to key questions and decisions.

The Quantitative Clinical Pharmacology teams in Sweden work in the therapy =
areas of RIA (Respiratory, Inflammation and Autoimmune diseases) and CVMD (=
Cardiovascular and Metabolic Disease). For these teams we are looking for t=
alented and engaged Clinical Pharmacometricians (entry, senior and principa=
l levels). We recognize the value of diversity and look for motivated indiv=
iduals with modeling backgrounds in pharmacometrics, statistics or engineer=
ing. You will have an opportunity to be part of our exciting journey!

The role

You will play a key role using a variety of innovative quantitative methods=
 to provide modeling support for planning, interpretation and decision maki=
ng in clinical development projects. This work includes integration of rele=
vant data, such as dose information, pharmacokinetics, biomarkers and clini=
cal endpoints within and across studies, compounds and development stages. =
Support to informative trial designs using simulations and efficient modeli=
ng statistics is an important focus area for us. An area to grow is systems=
 pharmacology and mechanistic modeling approaches for more informative tran=
slation of disease and drug knowledge.

You will be expected to use M&S to influence study and program designs and =
decisions. You will also be writing and contributing to internal and regula=
tory submission documents related to pharmacometrics. We support and encour=
age external visibility including presenting at scientific meetings as well=
 as publishing of our M&S contributions.

Qualifications

· Strong quantitative skills (e.g. experience in pharmacometrics,=
 statistical modeling, mechanistic modeling/systems pharmacology, quantitat=
ive translational scaling, model-based meta-analyses).

· Experience in drug development including relevant applications =
of M&S

· Bachelor degree required with advanced degree preferred or equi=
valent relevant experience

· A clear demonstration of behaviors of

o Truth seeking rather than success seeking

o Agile responsiveness to scientific data

o Embracing of peer review as well as sharing of experiences and know-ho=
w

More information

For more information about the positions please contact: Ulf Eriksson at +4=
6 31 7761690 or Bengt Hamrén at +46 31 7762201

Welcome with your application no later than June 1, 2015.


http://jobs.astrazeneca.com/jobs/details/l1rMOL000001QR-clinical-pharmacome=
tricians-quantitative-clinical-pharmacology-early-clinical-development-



Bengt Hamrén, PhD
Quantitative Clinical Pharmacology Lead CVMD
___________________________________________________________________________=
__________________
AstraZeneca R&D Mölndal
Research and Development | Quantitative Clinical Pharmacology
SE 431 83 Mölndal, Sweden
T: +46 (0)31 776 22 01
Mobile: + 46 (0) 768-774811
e-mail: bengt.hamren_at_astrazeneca.com<mailto:name.surname_at_astrazeneca.com>

Please consider the environment before printing this e-mail

________________________________

Confidentiality Notice: This message is private and may contain confidentia=
l and proprietary information. If you have received this message in error, =
please notify us and remove it from your system and note that you must not =
copy, distribute or take any action in reliance on it. Any unauthorized use=
 or disclosure of the contents of this message is not permitted and may be =
unlawful.

Received on Wed May 06 2015 - 06:53:12 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:44:06 EDT